Grants per year
Personal profile
Research Interests
I joined Northwestern University in August 2017 as a tenured Professor in Urology. I previously served as a Professor of Microbiology and Immunology at the Medical University of South Carolina and the University of Washington. I obtained a PhD from the University of British Columbia in Canada followed by post-doctoral training in Fred Hutchinson Cancer Research Center (FHCRC) and a faculty position at the University of Washington. My research focuses on understanding how cancer cells edit the immune system with the ultimate goal to develop effective immune therapy to control cancers.
Research in my laboratory include these specific aspects: 1) mechanisms of cancer immune evasion; 2) development of novel cancer immunotherapy; 3) Immune therapy-related mucosal toxicity; 4) mechanisms of cancer therapeutic resistance; 4) cancer biomarker discovery. Prostate Cancer is one of my lab's main focus areas. I am also researching the NKG2D axis in tumors which can be applied to a broad spectrum of cancer types and autoimmunity.
Training Experience
| 2002 | Postdoctoral Fellowship, Fred Hutchinson Cancer Research Center |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, Genetics, University of British Columbia
… → 2000
MSc, Cell Biology, Peking University
… → 1991
Research interests keywords
- Cancer Biology
- Immune Regulation
- Inflammation
- Inflammatory Bowel Disease
- Interdisciplinary Research
- Prostate Cancer
Fingerprint
Dive into the research topics where Jennifer Donglan Wu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity
Wu, J. D. (PD/PI), Sosman, J. A. (Co-PD/PI), Yang, G.-Y. (Co-Investigator) & Mi, X. (Other)
8/1/23 → 7/31/28
Project: Research project
-
Overcoming androgen receptor-mediated prostate cancer resistance to immunotherapy
Wu, J. D. (PD/PI), Wu, J. D. (PD/PI) & Wu, J. D. (PD/PI)
U.S. Army Medical Research and Materiel Command
9/1/21 → 8/31/25
Project: Research project
-
SPORE in Prostate Cancer
Abdulkadir, S. A. (PD/PI), Abdulkadir, S. A. (PD/PI), Hussain, M. (Co-PD/PI), Hussain, M. (Co-PD/PI), Catalona, W. J. (Co-Investigator), Catalona, W. J. (Co-Investigator), Chakravarti, D. (Co-Investigator), Chakravarti, D. (Co-Investigator), Cooper, L. A. D. (Co-Investigator), Kim, K.-Y. A. (Co-Investigator), Kim, K.-Y. A. (Co-Investigator), Kim, K.-Y. A. (Co-Investigator), Morgans, A. K. (Co-Investigator), Morgans, A. K. (Co-Investigator), Murphy, A. B. (Co-Investigator), Murphy, A. B. (Co-Investigator), Ross, A. E. (Co-Investigator), Schiltz, G. E. (Co-Investigator), Schiltz, G. E. (Co-Investigator), VanderWeele, D. J. (Co-Investigator), Wei, J.-J. (Co-Investigator), Wei, J.-J. (Co-Investigator), Yang, R. (Co-Investigator), Yang, R. (Co-Investigator), Yu, J. (Co-Investigator), Yu, J. (Co-Investigator), Kocherginsky, M. (Other), Kocherginsky, M. (Other), Leikin, R. G. (Other), Leikin, R. G. (Other), Sosman, J. A. (Other), Sosman, J. A. (Other), Wu, J. D. (Other), Wu, J. D. (Other), Yang, X. J. (Other), Yang, X. J. (Other), Yang, R. (Other), Zhao, C. (Other) & Zhao, C. (Other)
9/1/21 → 7/31/26
Project: Research project
-
Pre-clinical development of a novel class of immunotherapeutic antibody for metastatic prostate cancer
Wu, J. D. (PD/PI)
CanCure LLC, National Cancer Institute
11/8/19 → 8/31/22
Project: Research project
-
Developing a MALDI/PET Early Warning Imaging System for Lethal Prostate Cancer
Wu, J. D. (PD/PI)
Washington University in St. Louis, U.S. Army Medical Research and Materiel Command
9/30/19 → 9/29/23
Project: Research project
-
CD8+ T cells sustain antitumor response by mediating crosstalk between adenosine A2A receptor and glutathione/GPX4
Chen, S., Fan, J., Xie, P., Ahn, J., Fernandez, M., Billingham, L. K., Miska, J., Wu, J. D., Wainwright, D. A., Fang, D., Sosman, J. A., Wan, Y., Zhang, Y., Chandel, N. S. & Zhang, B., Apr 15 2024, In: Journal of Clinical Investigation. 134, 8, e170071.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma
Kim, S., Chung, H., Kwak, J. E., Kim, Y. R., Park, C. H., Kim, Y., Cheong, J. W., Wu, J., Shin, E. C., Cho, H. & Kim, J. S., Jan 8 2024, In: Journal for immunotherapy of cancer. 12, 1, e007886.Research output: Contribution to journal › Article › peer-review
Open Access -
Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges
Wu, J., Jul 2024, In: BioDrugs. 38, 4, p. 499-509 11 p.Research output: Contribution to journal › Review article › peer-review
Open Access1 Scopus citations -
The Human Soluble NKG2D Ligand Differentially Impacts Tumorigenicity and Progression in Temporal and Model-Dependent Modes
Serritella, A. V., Saenz-Lopez Larrocha, P., Dhar, P., Liu, S., Medd, M. M., Jia, S., Cao, Q. & Wu, J. D., Jan 2024, In: Biomedicines. 12, 1, 196.Research output: Contribution to journal › Article › peer-review
Open Access -
Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence
Johnson, M., Bell, A., Lauing, K. L., Ladomersky, E., Zhai, L., Penco-Campillo, M., Shah, Y., Mauer, E., Xiu, J., Nicolaides, T., Drumm, M., McCortney, K., Elemento, O., Kim, M., Bommi, P., Low, J. T., Memon, R., Wu, J., Zhao, J. & Mi, X. & 10 others, , 2023, In: Clinical Cancer Research. 29, 23, p. 4973-4989 17 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations
Datasets
-
Additional file 1 of Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
Basher, F. (Contributor), Dhar, P. (Contributor), Wang, X. (Creator), Wainwright, D. A. (Creator), Zhang, B. (Creator), Sosman, J. (Creator), Ji, Z. (Creator) & Wu, J. D. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.12456779, https://springernature.figshare.com/articles/Additional_file_1_of_Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_reprograms_NK_cell_homeostatic_survival_and_function_and_enhances_melanoma_response_to_PDL1_blockade_therapy/12456779
Dataset
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy
Zhang, J. (Creator), Larrocha, P.S.-L. (Creator), Zhang, B. (Creator), Wainwright, D. (Creator), Dhar, P. (Creator) & Wu, J. D. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.c.4643378, https://springernature.figshare.com/collections/Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_provides_dual_co-stimulation_of_CD8_T_cells_and_enables_sMIC_tumors_respond_to_PD1_PD-L1_blockade_therapy/4643378
Dataset
-
Additional file of Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
Basher, F. (Creator), Dhar, P. (Creator), Wang, X. (Creator), Wainwright, D. A. (Creator), Zhang, B. (Creator), Sosman, J. (Creator), Ji, Z. (Creator) & Wu, J. D. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.12872204, https://springernature.figshare.com/articles/dataset/Additional_file_of_Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_reprograms_NK_cell_homeostatic_survival_and_function_and_enhances_melanoma_response_to_PDL1_blockade_therapy/12872204
Dataset
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
Basher, F. (Creator), Dhar, P. (Creator), Wang, X. (Creator), Wainwright, D. A. (Creator), Zhang, B. (Creator), Sosman, J. (Creator), Ji, Z. (Creator) & Wu, J. D. (Creator), figshare, 2020
DOI: 10.6084/m9.figshare.c.5014769.v2, https://springernature.figshare.com/collections/Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_reprograms_NK_cell_homeostatic_survival_and_function_and_enhances_melanoma_response_to_PDL1_blockade_therapy/5014769/2
Dataset
-
Additional file 1: of Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy
Zhang, J. (Creator), Larrocha, P.S.-L. (Creator), Zhang, B. (Creator), Wainwright, D. (Creator), Dhar, P. (Creator) & Wu, J. D. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.9730352, https://springernature.figshare.com/articles/presentation/Additional_file_1_of_Antibody_targeting_tumor-derived_soluble_NKG2D_ligand_sMIC_provides_dual_co-stimulation_of_CD8_T_cells_and_enables_sMIC_tumors_respond_to_PD1_PD-L1_blockade_therapy/9730352
Dataset